Healius Limited has provided a FY26 trading update that reveals a company navigating conflicting pressures. The company expects underlying EBITDA between 259 million and 264 million dollars, with EBIT guidance of 30 million to 35 million dollars. Concurrent with these financial projections, Healius has engaged UBS Securities to explore a sale of Agilex Biolabs, its standalone diagnostics business, following unsolicited approaches from potential buyers. The decision to consider divesting Agilex while the business posts strong 13.7 percent revenue growth suggests the company may be prioritizing debt management or shareholder returns over growth in that segment.
Healius’ core pathology operations present a mixed picture. Pathology volumes grew 1.2 percent and revenue grew 3.5 percent in the first half of 2026, though the longer view tells a different story. For the ten months to April 2026, volumes have actually declined 0.4 percent while revenue increased 2.4 percent, indicating the company is extracting more revenue per test despite lower utilization. GP attendances declined 1.5 percent in the first half and 1.0 percent from January to March. These soft volumes suggest either demand weakness or market competition. The one bright spot has been cost management. Pathology costs increased just 1.1 percent for the ten months to April, down from 1.9 percent at December 2025, benefiting from labor efficiencies expected to accelerate in the second half.
The outlook grows cloudier when Fair Work Commission decisions enter the picture. The Commission’s initial findings on gender-based undervaluation of pathology roles will cost Healius approximately 1.8 million dollars in Q4 2026 alone. Pathology Collectors received pay increases from 1 April 2026, with further increases due on 1 January 2027. Health Professionals will see phased increases over five years commencing July 2026. These wage pressures arrive as the Federal Budget delivered no new funding for pathology and maintained indexation freezes on most test rebates, creating a genuine cost squeeze for the sector.
For investors, this announcement signals that Healius faces margin compression without intervention. The company has cut staff, closed collection centers, and closed regional laboratories to manage costs, with out-of-pocket charging emerging as a final lever to bridge the funding gap. These actions carry reputational and volume risks in a sector critical to primary healthcare. The potential Agilex sale, while separating a growth asset, may provide capital to strengthen the core pathology business or reduce leverage. Healius management will have the opportunity to explain guidance assumptions and the strategic logic behind the Agilex review when presenting full-year results in August, or sooner if required. Investors should closely monitor the trajectory of pathology volumes in the coming months and developments on the Agilex sale process, as these will determine whether the company can stabilize cash generation amid structural sector challenges. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Healius Limited (ASX: HLS)
Healius Limited is Australia’s second-largest pathology provider, operating a network of pathology laboratories, diagnostic imaging centres, and day hospitals across the country. The company operates through Pathology and Imaging segments, providing medical laboratory services and diagnostic imaging services to patients and healthcare providers. Healius maintains around 2,000 collection sites and nearly 100 pathology laboratories throughout Australia.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
